SCHEMBL20147581

SCHEMBL20147581

CC(C)N1CCC(NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.68
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 6/20 0.60
SLC6A12 P48065 1/20 0.57
TMEM97 Q5BJF2 1/20 0.57
MCHR1 Q99705 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
CTSB P07858 1/20 0.56
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
CTSC P53634 1/20 0.56
USP2 O75604 1/20 0.56
TSHR P16473 1/20 0.56
MEN1 O00255 3/20 0.55
HTR1A P08908 1/20 0.55
HTR7 P34969 1/20 0.55
ACKR3 P25106 1/20 0.54
POLB P06746 1/20 0.53
CCR3 P51677 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21940956 0.87 HRH3 (0.70) HRH3ACKR3
SCHEMBL14924418 0.87 HRH3 (0.70) HRH3NPC1RAB9AKMT2AMEN1
SCHEMBL14923986 0.86 HRH3 (0.68) HRH3MCHR1
SCHEMBL18389994 0.85 HRH3 (0.67) HRH3NPC1RAB9AKMT2AMCHR1
SCHEMBL20147585 0.84 KMT2A (0.61) HRH3KMT2ATSHRMEN1ACKR3
SCHEMBL10210770 0.84 NPC1 (0.59) HRH3NPC1RAB9AKMT2ASLC6A12
SCHEMBL7377018 0.84 MCHR1 (0.59) HRH3NPC1RAB9AKMT2ASLC6A12
SCHEMBL4749226 0.84 NPC1 (0.67) NPC1RAB9AKMT2ASLC6A12TMEM97
Fk-962 SCHEMBL239762 0.81 KMT2A (0.69) NPC1RAB9AKMT2ASLC6A12TMEM97
SCHEMBL532160 0.81 RAB9A (0.83) NPC1RAB9AKMT2ASLC6A12TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20220411396-A1 TRIOXOLANE AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-12-29 US disclosed
US-11072594-B2 Trioxolane agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-27 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-20200140406-A1 TRIOXOLANE AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-05-07 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411396-A1 TRIOXOLANE AGENTS ABCB4, SLC10A1, SLC10A2 HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885
US-11072594-B2 Trioxolane agents ABCB4, SLC10A1, SLC10A2 HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885
US-20200140406-A1 TRIOXOLANE AGENTS ABCB4, SLC10A1, SLC10A2 HRH3 2136/4885NPC1 252/4885RAB9A 2056/4885
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 HRH3 1000/4885NPC1 4145/4885RAB9A 632/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885NPC1 4145/4885RAB9A 632/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 HRH3 1000/4885NPC1 4145/4885RAB9A 632/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885NPC1 4145/4885RAB9A 632/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885NPC1 4145/4885RAB9A 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.